182 related articles for article (PubMed ID: 11224617)
1. Decision analysis for the cost-effective management of recurrent colorectal cancer.
Park KC; Schwimmer J; Shepherd JE; Phelps ME; Czernin JR; Schiepers C; Gambhir SS
Ann Surg; 2001 Mar; 233(3):310-9. PubMed ID: 11224617
[TBL] [Abstract][Full Text] [Related]
2. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
3. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
5. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
[TBL] [Abstract][Full Text] [Related]
8. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
[TBL] [Abstract][Full Text] [Related]
9. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck.
Hollenbeak CS; Lowe VJ; Stack BC
Cancer; 2001 Nov; 92(9):2341-8. PubMed ID: 11745289
[TBL] [Abstract][Full Text] [Related]
11. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
[TBL] [Abstract][Full Text] [Related]
12. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
13. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography.
Klose T; Leidl R; Buchmann I; Brambs HJ; Reske SN
Eur J Nucl Med; 2000 Oct; 27(10):1457-64. PubMed ID: 11083533
[TBL] [Abstract][Full Text] [Related]
14. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
15. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
16. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
17. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
18. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Ann Nucl Med; 2002 Jun; 16(4):263-71. PubMed ID: 12126096
[TBL] [Abstract][Full Text] [Related]
19. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
20. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]